| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_c8d0d3f44652ec2f92273ae488dc4a8d |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-08
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/Y02A50-30 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-7036
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-7008
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P11-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-70
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P31-04
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P31-06
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07H15-224
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07H17-04 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P31-04
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-7008 |
| filingDate |
2011-09-12-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate |
2016-12-10-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_d634330ddb3ea2c2684e70186c6f951e
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_d8bfe6ba0b35c2edbd9000e2b06051b8 |
| publicationDate |
2016-12-10-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
RU-2604665-C2 |
| titleOfInvention |
Treatment of bacterial infectious diseases |
| abstract |
FIELD: pharmaceutics. n SUBSTANCE: group of inventions refers to a pharmacological treatment of bacterial infectious diseases in humans. Use of apramycin is disclosed or apramycin derivatives to treat bacterial infectious diseases in humans; its use for preparing a drug for treating bacterial infectious diseases in a human and a method of treating thereof. n EFFECT: it is demonstrated that apramycin surprisingly does not have the expected high level of toxicity observed with related aminoglycoside antibiotics, in particular, it has low risk of cochleatoxicity and nephrotoxicity, that makes it applicable in medicine for treating a human; besides, effectiveness of apramycin in vitro against tuberculosis and non-tuberculous mycobacteria strains is shown. n 10 cl, 10 tbl, 12 ex, 2 dwg |
| priorityDate |
2010-09-13-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |